To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency.
📊
Key Findings & Data:This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency.
💡
Conclusion & Impact:To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
This consensus report includes expert opinions and recommendations regarding the screening, and if necessary, the follow-up, pro-phylaxis, and treatment of hepatitis B before the treatment in patients who will undergo immunosuppressive therapy due to the risk of hepatitis B reactivation emergency. To increase awareness regarding the risk of hepatitis B reactivation in immunosuppressive patients, academicians from several university health research and training centers across Turkey came together and discussed the importance of the subject, current status, and issues in accordance with the current literature data and presented solutions.
🔖
Cite This Article
AYGEN, B., DEMİR, A. M., GÜMÜŞ, M., KARABAY, O., KAYMAKOĞLU, S., KÖKSAL, A. Ş., KÖKSAL, İ., ÖRMECİ, N., TABAK, Ö. F. (2018). Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 3, 259–269. https://ajindex.com/articles/410058
Uslu Tutar N, Ozgul E, Oguz D, Cakir B, Tarhan NÇ, Coskun M. An uncommon cause of acute abdomen-epiploic appendagitis: CT findings. Turk J Gastroenterol 2007; 18: 107-10
Leclercq P, Dorthu L. Epiploic appendagitis. CMAJ: Canadian Med-ical Association Journal 2010; 182: 939. [CrossRef] 3. Singh AK, Gervais DA, Hahn PF, Sagar P, Mueller PR, Novelline RA. Acute epiploic appendagitis and its mimics. Radiographics 2005; 25: 1521-34. [CrossRef] 4. Pogorelić Z, Stipić R, Druzijanić N, et al. Torsion of epiploic append-age mimic acute appendicitis. Coll Antropol 2011; 35: 1299-302
Legome EL, Belton AL, Murray RE, Rao PM, Novelline RA. Epiplo-ic appendagitis: the emergency department presentation. J Emerg Med 2002; 22: 9-13. [CrossRef]